Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Additional analysis: supplementary data including a continuation rule as in Roche model

Further information presented at FAD meeting on 6 April 2010

Comparison of model results with assumptions from Roche model
Table S11 of the addendum report (page 84), repeated below for convenience, showed results for comparison with the Roche model. In preparing this addendum, minor transcription errors affecting the last two lines of the table became apparent. These have been corrected below.

Table S11 Comparison of model results with assumptions from Roche model (corrected)

Model	ADA - DMARDs	ETN – DMARDs	IFX - DMARDs	RTX - DMARDs	ABT - DMARDs
BRAM Reference	34300	38900	36100	21100	38400
Changing HAQ increase	31900	33500	32000	17200	41500
Changing short-term quit rate	23800	25100	27400	20500	26400
Changing both	24500	24500	27200	18000	31200
Roche*	17300	18000	16200	5300	21500

*Results for comparisons not involving rituximab are inferred from total costs and QALYs reported by Roche (Tables 101-105, pages 226-228 of the company submission).

Changing short-term quit rate

For this scenario, all inputs to the model were as for the BRAM reference case, except that the inputs in Table S9 of the addendum report (page 83) replaced the values in Table 9 (pages 60-61). The detailed results were then as follows

Treatment	Mean Cost	95% Credible Interval		Mean QALY	95% Credible Interval	
ADA	61700	56500	67200	2.56	-2.63	7.73
ETN	60300	54900	66200	2.47	-2.71	7.61
IFX	62300	54400	70200	2.49	-2.71	7.64
RTX	66500	60000	73000	2.91	-2.07	7.93
ABT	70500	64400	76800	2.82	-2.24	7.85
DMARDs	44500	39100	49900	1.83	-3.68	7.39

Comparison	Diff Cost	95% Credible Interval		Diff QALY	95% Credible Interval	
ADA – DMARDs	17300	15800	18800	0.73	0.32	1.19
ETN – DMARDs	15900	14300	17600	0.63	0.27	1.05
IFX – DMARDs	17900	11700	24000	0.65	0.26	1.11
RTX – DMARDs	22000	18900	25200	1.07	0.45	1.79
ABT – DMARDs	26100	23000	29400	0.99	0.43	1.60

Diff = difference, calculated by subtracting the value for the strategy named second from the value for the strategy named first.

Comparison	ICER	95% Credible Interval		Proportion of cases CE at	
				£20,000/QALY	£30,000/QALY
ADA – DMARDs	23800	14300	54600	0.25	0.74
ETN – DMARDs	25100	14900	59100	0.20	0.69
IFX - DMARDs	27400	15400	63800	0.14	0.60
RTX - DMARDs	20500	12500	48700	0.44	0.85
ABT - DMARDs	26400	16300	59300	0.15	0.65

CE = cost-effective. The proportion of cases cost-effective relates to the strategy given first on each line.